Division of Nephrology

Medicine & Life Sciences

1. Kidney 100%
2. Acute Kidney Injury 85%
3. Chronic Renal Insufficiency 79%
4. Kidney Diseases 51%
5. Nephrologists 46%
6. Transplants 43%
7. Meta-Analysis 41%
8. Plasminogen Activators 36%
9. Myofibroblasts 34%
10. Continuous Renal Replacement Therapy 34%
11. Fibroblasts 33%
12. Systematic Reviews 32%
13. Chronic Kidney Failure 28%
14. Fibrosis 25%
15. Focal Segmental Glomerulosclerosis 25%
16. Lung 24%
17. triptolide 23%
18. Annexin A2 22%
19. Low Density Lipoprotein Receptor-Related Protein-1 21%
20. Pulmonary Fibrosis 21%
21. Lipoid Nephrosis 21%
22. Creatinine 20%
23. Liver Transplantation 19%
24. Proteinuria 18%
25. Tissue Donors 17%
26. Renal Dialysis 17%
27. Transforming Growth Factors 17%
28. Mortality 17%
29. Sleep Apnea Syndromes 16%
30. Catenins 16%
31. Macrophages 16%
32. Urine 16%
33. Apoptosis 15%
34. Bleomycin 15%
35. Basement Membrane 15%
36. Epithelial Cells 15%
37. Kidney Transplantation 14%
38. Tissue and Organ Procurement 13%
39. Dialysis 13%
40. Immunoglobulin Heavy Chains 13%
41. Vascular Endothelial Growth Factor A 13%
42. Wounds and Injuries 12%
43. Glomerular Filtration Rate 12%
44. Observational Studies 12%
45. Iran 12%
46. integrin-linked kinase 12%
47. Hyperoxia 12%
48. Allografts 12%
49. Serum 12%
50. Coronavirus 12%
51. Therapeutics 12%
52. Idiopathic Pulmonary Fibrosis 11%
53. Cell Survival 11%
54. Disease Progression 11%
55. Biomarkers 11%
56. Mesenchymal Stem Cells 11%
57. Mentoring 11%
58. Rituximab 11%
59. MicroRNAs 11%
60. Autoimmunity 11%
61. Transplant Recipients 11%
62. Transgenic Mice 11%
63. Coculture Techniques 11%
64. Laminin 10%
65. Odds Ratio 10%
66. Biopsy 10%
67. Renal Replacement Therapy 10%
68. Calcineurin Inhibitors 9%
69. 90-kDa Ribosomal Protein S6 Kinases 9%
70. Immunosuppression 9%
71. Endothelial Cells 9%
72. Cytokines 9%
73. Mycophenolic Acid 9%
74. Lung Injury 9%
75. Oxidative Stress 9%
76. Hepatocyte Growth Factor 9%
77. Incidence 9%
78. Mesangial Cells 9%
79. Randomized Controlled Trials 9%
80. Peptide Hydrolases 8%
81. Proteins 8%
82. Smoldering Multiple Myeloma 8%
83. microcystin 8%
84. Purpura Fulminans 8%
85. Antigens 8%
86. B-Lymphocytes 8%
87. cyanoginosin LR 8%
88. BK Virus 8%
89. Body Mass Index 8%
90. Transgenes 8%
91. Phosphorylation 7%
92. Patient Outcome Assessment 7%
93. Graft Survival 7%
94. Medical Order Entry Systems 7%
95. Maintenance 7%
96. Alitretinoin 7%
97. Stakeholder Participation 7%
98. Renal Insufficiency 7%
99. Smooth Muscle 7%